Skip to main content

x

Main navigation

HOME
Content

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Search

Breadcrumb

Home /
/
Duis quis nibh eget urna convallis

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Duis quis nibh eget urna convallis

17 March 2017 / Comments

Submitted by

ApexOnco Editorial Team

on 17 March 2017

Recent Quick take

Xencor “still committed” to oncology

9 September 2024
IN8bio cuts costs on registrational delay

5 September 2024
Innovent revives its US checkpoint plan

4 September 2024
Imugene goes for a cytokine boost

2 September 2024
Daiichi broadens its Vanflyta net

2 September 2024
Next up for SHP2: partner buy-in

30 August 2024
Two Keytruda setbacks in early cancer settings

29 August 2024
Repare shelves its early work

29 August 2024

Load More

Most Popular

ESMO 2023 – Pluvicto’s big splash gets an early preview

17 October 2023
CCR8 expectations

18 April 2024
AstraZeneca's phase 3 TIGIT surprise

2 November 2023
Revolution pushes home its pan-KRAS advantage

27 February 2024
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition

22 October 2023
The month ahead: May’s remaining events

14 May 2024

Subscribe to our newsletter

Contact
|
Terms & Conditions
|
Privacy Policy
|
Cookies Policy